Lung Cancer
Studies from Japan and the United Kingdom describe new findings in lung cancer research
Published in Drug Week, September 8th, 2006
Study 1: Previously untreated small-cell lung cancer (SCLC) could be treated by irinotecan combined with carboplatin.
According to a recently published article from Japan, "To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were: chemotherapy-naive, SCLC, good performance status (PS: 0-2), age {{<=}}75 years, and adequate organ function. The patients' characteristics were: male/female 56/5; PS 0/1/2=19/38/4; median age (range) 68 years (51-75 years); limited disease (LD)/extensive...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-09-08)
More Articles from Drug Week
- Drug Delivery
Low temperature sensitive liposome-doxorubicin may improve drug delivery to solid tumors - Drug Development
Human primary renal cells used as model for toxicity assessment of chemotherapeutic drugs - Osteoarthritis
IDEA reports positive phase III results for targeted analgesic IDEA-033 - Pharmacokinetics
Interactions between simvastatin and omega-3-acid ethyl esters were examined - Systemic Lupus Erythematosus
Human Genome Sciences launches phase III clinical development program for LymphoStat-B - Acute Myeloid Leukemia
Dacogen (decitabine) for Injection receives U.S. orphan drug designation for patients with AML - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
